VRTXVertex Pharmaceuticals Incorporated

$125B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$941M+25.1% YoY

Gross Profit

$806M85.6% margin

Operating Income

$270M28.7% margin

Net Income

$267M28.4% margin

EPS (Diluted)

$1.03

QoQ Revenue Growth

+9.7%

Cash Flow

Operating Cash Flow

$464M

Free Cash Flow

$447M

Stock-Based Comp.

$90M

Balance Sheet

Total Assets

$7.0B

Total Liabilities

$2.0B

Stockholders' Equity

$5.1B

Cash & Equivalents

$3.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$941M	$752M	+25.1%
Gross Profit	$806M	$648M	+24.4%
Operating Income	$270M	$173M	+56.2%
Net Income	$267M	$207M	+29.0%

Revenue Segments

SYMDEKO/SYMKEVI

$362M38%

ORKAMBI

$316M34%

KALYDECO

$262M28%

Geographic Segments

UNITED STATES

$701M62%

Non-US

$241M21%

Europe

$180M16%

VRTX Q2 2019 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena